This rare condition is a genetic syndrome that affects several parts of the body at the same time. People with this syndrome usually have signs of Alport syndrome (blood in the urine, kidney problems, and later hearing loss), intellectual disability (learning and developmental delays), midface hypoplasia (the middle part of the face is under-developed, giving a flat look with a depressed nasal bridge), and elliptocytosis (many red blood cells are oval or “elliptical” instead of round). The cause is usually a small missing piece of DNA on the X chromosome at Xq22.3 that removes several neighboring genes at once (a “contiguous gene deletion”). Loss of these genes—especially COL4A5 (important for kidney and ear structures), ACSL4/FACL4 (brain lipid metabolism), and AMMECR1—explains why kidneys, hearing, facial development, blood cells, and learning are all involved. Because the change is on the X chromosome, males are typically more severely affected.
Alport syndrome–intellectual disability–midface hypoplasia–elliptocytosis syndrome is a rare X-linked genetic condition caused by a small missing piece of DNA on the X chromosome (region Xq22.3). Several neighboring genes are deleted together. Because many genes are lost at the same time, several body systems are affected at once. The typical pattern includes:
Alport syndrome (kidney disease with blood and protein in urine, hearing loss, and specific eye changes),
Intellectual disability or developmental delay,
Midface hypoplasia (the middle part of the face is under-grown, giving a flattened midface and depressed nasal bridge), and
Elliptocytosis (red blood cells are oval/elliptical; some people develop mild to severe hemolytic anemia).
Doctors often call this cluster the AMME complex (A = Alport; M = mental disability; M = midface hypoplasia; E = elliptocytosis). It happens most often in people who have only one X chromosome (typically males). Family members with two X chromosomes may be unaffected or have milder signs. The deletion typically includes COL4A5 (drives Alport syndrome) and can include ACSL4 (FACL4) and AMMECR1, which contribute to intellectual disability, midface hypoplasia, and elliptocytosis. Disease Ontology+4Frontiers+4Orpha.net+4
Key biology in simple words:
COL4A5 helps build type IV collagen in the kidney filter (the glomerular basement membrane) and in inner ear and eye tissues. When it is missing or faulty, the kidney filter scars over time, and hearing and eye problems develop — this is Alport syndrome. PMC
AMMECR1 is a nearby X-linked gene. Changes in AMMECR1 are linked to midface hypoplasia, elliptocytosis, short stature, and sometimes hearing issues. Journal of Medical Genetics+2PubMed+2
ACSL4 (FACL4) loss is associated with intellectual disability and other neurodevelopmental features seen in the contiguous deletion. PubMed+1
Doctors often call the condition AMME syndrome (A = Alport, M = mental/intellectual disability, M = midface hypoplasia, E = elliptocytosis). It is usually X-linked, which means it mainly affects boys/men, and female relatives may have few or mild signs. In many patients, the problem comes from a small missing piece (microdeletion) on the X chromosome at Xq22.3 that removes several genes at once, including COL4A5 (causes Alport syndrome), ACSL4/FACL4 (linked to X-linked intellectual disability), and AMMECR1 (important for the typical facial features and elliptocytosis). PubMed+3Genetic Diseases Center+3NCBI+3
Researchers have also found families where a mutation in the AMMECR1 gene alone causes many of the same features (midface hypoplasia, short stature, hearing loss, and elliptocytosis), sometimes with or without kidney disease. This shows that AMMECR1 is a key driver of the facial and blood findings. PubMed+2PubMed+2
Other names
AMME syndrome
AMME complex
Alport syndrome–mental retardation–midface hypoplasia–elliptocytosis
Alport syndrome–intellectual disability–midface hypoplasia–elliptocytosis
These names refer to the same clinical picture and the well-known X-linked deletion at Xq22.3. Diseases+1
Types
Because this is rare, there isn’t a single official “type list.” Clinicians often group patients by the genetic cause and by which features are present.
Classic contiguous-gene (microdeletion) AMME – a hemizygous deletion at Xq22.3 that removes COL4A5 + AMMECR1 + ACSL4 (and sometimes nearby genes like TMEM164 or KCNE5). This form typically shows kidney disease (Alport), midface hypoplasia, intellectual disability, hearing loss, and elliptocytosis. GeneCards+3Genetic Diseases Center+3PubMed+3
AMMECR1-mutation AMME-like spectrum – a change in AMMECR1 without the larger deletion. Patients often have midface hypoplasia, short stature, hearing issues, and elliptocytosis; kidney disease may be mild or absent. PubMed+1
ACSL4-driven intellectual disability within the deletion – in some deletions, loss of ACSL4 is believed to contribute strongly to cognitive impairment. PubMed+2Wiley Online Library+2
Female carriers with variable expression – due to X-inactivation, females who carry the deletion or mutation can show a range from no symptoms to mild hearing loss, subtle facial features, or mild blood changes. (This is a general principle for X-linked disorders; AMME carrier descriptions vary across reports.) Genetic Diseases Center
Causes
Each “cause” below describes a biologic or genetic reason that can produce the AMME picture or parts of it.
Xq22.3 contiguous gene deletion removing COL4A5, AMMECR1, ACSL4: one missing stretch takes out several genes at once, creating the full AMME combination. Genetic Diseases Center+1
COL4A5 loss (within the deletion): causes the Alport kidney and ear findings by damaging type IV collagen in glomerular and cochlear basement membranes. PubMed
AMMECR1 loss-of-function: disrupts a nuclear protein linked to growth, bone, heart, kidney, and red-cell shape, driving midface hypoplasia and elliptocytosis. NCBI+1
ACSL4 (FACL4) deletion/mutation: impairs brain lipid metabolism and neuronal development, contributing to X-linked intellectual disability. PubMed+1
Extension of the deletion into nearby genes (e.g., TMEM164, KCNE5): may add features like growth issues or cardiac findings in some patients. Wiley Online Library+1
De novo events: the deletion or mutation can happen anew in the child, with no family history. (Common in rare microdeletion syndromes; reported in Xq22.3-q23 cases.) PubMed
X-linked inheritance: males are typically affected because they have only one X chromosome; females can be carriers with variable features. Genetic Diseases Center
Basement-membrane fragility from COL4A5 loss: leads to blood and protein leaking in urine and progressive kidney scarring. (Core Alport mechanism.) PubMed
Abnormal red-cell membrane mechanics from AMMECR1 pathway disruption: favors elliptocytosis and sometimes hemolytic anemia. PubMed
Hearing pathway vulnerability: Alport-related inner-ear basement membranes are fragile, giving sensorineural hearing loss. Genetic Diseases Center
Neurodevelopmental pathway disruption via ACSL4: lipid signaling needed for synapses is disturbed, affecting learning and behavior. Wiley Online Library
Gene dosage effects: how large the deletion is (which and how many genes are lost) shapes which features appear and how severe they are. PubMed+1
Mosaicism (rare): if only some cells carry the change, signs may be uneven or milder. (Principle in X-linked CNVs; specific AMME mosaicism has been suggested in case discussions.) Genetic Diseases Center
Red-cell skeleton sensitivity: in hereditary elliptocytosis generally, changes in cytoskeletal proteins make cells oval and fragile; AMME taps similar mechanics, though through a different upstream gene. NCBI
Developmental facial bone growth disturbance from AMMECR1 dysfunction: leads to midface hypoplasia. PubMed
Cardiac conduction or structure influence when deletions include heart-expressed genes (e.g., KCNE5): may explain occasional ECG/echo findings. GeneCards
Short stature pathways: reported in AMMECR1-mutation families, suggesting growth-regulating roles. PubMed
Vision/craniofacial connective-tissue effects: midface bones and soft tissues rely on tightly regulated development that AMMECR1 seems to affect. PubMed
Family transmission through carrier mothers: typical for X-linked conditions; pattern helps explain recurrent cases in boys in a family. Genetic Diseases Center
Broader Xq22.3 microdeletions: when the lost region spans farther (e.g., to TMEM164/AMMECR1), the phenotype (set of signs) becomes more recognizable: short stature, midface hypoplasia, intellectual delay, and elliptocytosis. Wiley Online Library
Common symptoms and signs
Not everyone has all of these, and severity varies with the exact genes involved.
Blood in urine (microscopic or visible) – a hallmark of Alport kidney disease. Genetic Diseases Center
Protein in urine – shows kidney filter damage and may grow over time. Genetic Diseases Center
Swelling of legs or around eyes – if kidneys leak protein or function drops. Genetic Diseases Center
Gradual hearing loss (usually high-pitch first) – from inner-ear membrane fragility. Genetic Diseases Center
Learning or developmental delay – from ACSL4/AMMECR1 pathway effects. PubMed
Midface hypoplasia – flatter cheeks, depressed nasal bridge, retruded midface. NCBI
Short stature – reported in several AMMECR1-related families. PubMed
Elliptocytosis – many red blood cells are oval; some people get anemia, jaundice, or fatigue if cells break easily. Genetic Diseases Center+1
Tiredness and pale skin – when anemia is present. NCBI
Facial differences noticed in childhood** – small chin or midface, depressed nasal bridge. NCBI
High blood pressure – can appear as kidney disease progresses. Genetic Diseases Center
Behavior or attention issues – sometimes accompany intellectual disability. PubMed
Cardiac findings – occasional rhythm or structural changes have been described in the broader deletion spectrum. NCBI+1
Family pattern – other male relatives may have hearing loss/kidney issues; female relatives may have mild signs. Genetic Diseases Center
Growth faltering in childhood – ties to the AMMECR1 spectrum. PubMed
Diagnostic tests
A) Physical examination
1) General growth and vital signs
The doctor measures height, weight, head size, and blood pressure. Slower growth and high blood pressure can point toward kidney involvement and the AMMECR1 spectrum. PubMed+1
2) Facial examination
Clinicians look for a depressed nasal bridge, flatter midface, or retrusion. These visible clues support the diagnosis when combined with kidney, hearing, and blood findings. NCBI
3) Ear, nose, and throat (bedside)
A focused exam plus simple hearing screens help pick up early hearing loss typical of Alport involvement. Genetic Diseases Center
4) Family history and pedigree drawing
Charting which relatives are affected (especially males on the mother’s side) helps reveal the X-linked pattern. Genetic Diseases Center
B) Manual/clinical tests
5) Tuning-fork hearing tests (Rinne and Weber)
Quick bedside checks suggest sensorineural hearing loss, prompting full audiology testing. Genetic Diseases Center
6) Urine dipstick at the visit
A simple strip test that can show blood and protein in urine—classic pointers toward Alport kidney disease. Genetic Diseases Center
7) Peripheral blood smear review
A technologist or hematologist looks at red cells under a microscope. Seeing many elliptocytes supports the “E” in AMME. Genetic Diseases Center+1
8) Developmental screening
Standardized bedside tools (e.g., for language and motor skills) can flag delays that merit formal neuropsychological testing. PubMed
C) Laboratory and pathological tests
9) Complete blood count (CBC) and reticulocyte count
Shows anemia if red cells break down quickly; reticulocytes rise when the bone marrow tries to replace lost cells. NCBI
10) Hemolysis panel (bilirubin, LDH, haptoglobin)
These labs help confirm hemolysis when elliptocytosis causes red-cell fragility. NCBI
11) Urinalysis with protein/albumin-to-creatinine ratio
Quantifies kidney leak. Rising protein loss suggests progression. Genetic Diseases Center
12) Serum creatinine and estimated GFR
Tracks kidney function over time, essential in Alport-related disease. Genetic Diseases Center
13) Red-cell membrane studies (e.g., ektacytometry)
Functional testing of red-cell deformability helps characterize hereditary elliptocytosis and its severity. NCBI
14) Genetic microarray or CNV testing
Looks for the Xq22.3 microdeletion that defines classic AMME (loss of COL4A5, AMMECR1, ACSL4, ± neighbors). Genetic Diseases Center+1
15) Targeted gene sequencing
If a deletion is not found, sequencing AMMECR1 and ACSL4 can detect point mutations causing an AMME-like picture. PubMed+1
D) Electrodiagnostic tests
16) Pure-tone audiometry
Measures hearing thresholds across pitches; typical Alport-related hearing loss starts in higher frequencies. Genetic Diseases Center
17) Auditory brainstem response (ABR)
An objective test (useful in infants or non-verbal patients) that checks the hearing nerve and brainstem pathways. Genetic Diseases Center
E) Imaging and specialized studies
18) Renal ultrasound
Screens kidney size and structure; while often normal early, it rules out other causes of blood/protein in urine and follows chronic changes. Genetic Diseases Center
19) Echocardiogram and ECG (when indicated)
Used if the deletion includes heart-expressed genes or if there are murmurs, chest symptoms, or rhythm concerns. GeneCards+1
20) Brain MRI (selected cases)
Considered when development is significantly delayed or seizures/neurologic concerns are present, to assess brain structure and exclude other causes. (Imaging choice driven by clinical judgment in X-linked ID syndromes.) PubMed
Non-pharmacological treatments (therapies and other supports)
Genetic counseling – explains inheritance, family risks, testing of relatives, and reproductive choices (including prenatal and preimplantation options). Purpose: informed planning. Mechanism: clarifies X-linked transmission and gene deletions. Frontiers
Regular nephrology care – close monitoring of urine protein, kidney function, and blood pressure; early kidney-protective steps slow decline. Mechanism: treat risk factors before scarring worsens. PMC
Blood pressure self-monitoring – home BP checks guide treatment and reduce kidney damage risk. Mechanism: tight BP control protects glomeruli. PMC
Renal-protective diet – low-salt eating, controlled phosphorus, adequate but not excessive protein, healthy weight. Purpose: reduce proteinuria/edema and help CKD bone-mineral balance. KDIGO
Hearing support – early audiology, hearing aids when needed; consider cochlear implant evaluation if severe loss. Purpose: optimize communication and development. PMC
Speech-language therapy – helps language delay and speech clarity; improves school participation. Mechanism: intensive practice builds skills. Journal of Medical Genetics
Educational supports/IEP – tailored learning plans, special education, classroom accommodations. Purpose: maximize learning despite cognitive challenges. Frontiers
Occupational therapy – improves daily living skills, handwriting, sensory processing. Purpose: independence. Mechanism: task-specific training. Frontiers
Physiotherapy/exercise plan – safe aerobic and strength activities to maintain fitness, blood pressure, and mood. Mechanism: improves cardiovascular health. PMC
Vision care – periodic ophthalmology checks for Alport-related ocular changes; corrective lenses if needed. Purpose: preserve function. PMC
Avoid nephrotoxins – avoid NSAIDs when possible, avoid aminoglycosides unless essential, and limit contrast dyes. Purpose: protect kidneys already at risk. PMC
Infection prevention – routine vaccines; if spleen is removed (for severe elliptocytosis), ensure pneumococcal, Hib, and meningococcal vaccines and emergency antibiotics plan. Mechanism: reduces sepsis risk. UpToDate
Folate-rich diet for hemolysis – leafy greens, legumes; supports red blood cell production in elliptocytosis. Medscape
Psychological support – counseling for child and family; supports coping with chronic illness and learning needs. Purpose: mental well-being. Frontiers
Social work/care coordination – links to assistive services, disability resources, transplant preparation. Frontiers
Kidney-failure planning – timely education about dialysis options and transplant referral if kidney function declines. Mechanism: smoother transition, better outcomes. PMC
Gallstone surveillance when hemolysis is significant – ultrasound and early surgical referral if symptomatic stones occur. Mechanism: hemolysis increases pigment stones. Revista Nefrología
Hydration habits – steady fluid intake unless restricted for CKD; helps overall well-being and reduces stone risk. (Follow nephrologist guidance.) PMC
Sleep hygiene – regular sleep supports cognition, mood, and school performance. Purpose: daily functioning.
Safety education after splenectomy – fever is an emergency; medical alert ID. Mechanism: rapid antibiotics prevent overwhelming sepsis. UpToDate
Drug treatments
Important: doses must be individualized by your clinician based on age, kidney function, potassium level, and other conditions. The list below shows typical ranges and roles (not personal medical advice).
Kidney protection & blood pressure
Enalapril (ACE inhibitor) – Class: ACEi. Usual dose: 0.1–0.5 mg/kg/day in children (max per guidelines), 5–40 mg/day adults in 1–2 doses. Time: daily. Purpose: lower proteinuria and protect kidneys in Alport/CKD. Mechanism: blocks RAAS efferent arteriolar tone; reduces intraglomerular pressure. Side effects: cough, ↑potassium, kidney function bumps, teratogenic. Kidney International+1
Lisinopril (ACE inhibitor) – Class: ACEi. 2.5–40 mg once daily adults; pediatric per kg dosing. Purpose/mechanism/risks as above. PMC
Losartan (ARB) – Class: ARB. 25–100 mg/day adults. Purpose: alternative to ACEi to reduce proteinuria. Mechanism: blocks AT1 receptor. Side effects: ↑potassium, dizziness; do not combine with ACEi. PMC
Irbesartan/Candesartan (ARB options) – similar use to losartan when ACEi not tolerated. Same cautions on potassium and pregnancy. PMC
Amlodipine (calcium-channel blocker) – 2.5–10 mg/day adults. Purpose: control BP if ACEi/ARB alone not enough. Mechanism: vasodilation. Side effects: ankle edema, flushing. PMC
Furosemide (loop diuretic) – 20–120 mg/day adults; pediatric per kg. Purpose: treat edema, help BP control. Mechanism: increases salt/water excretion. Side effects: dehydration, low potassium, ototoxicity at high IV doses. PMC
Kidney & heart protection (select patients)
Dapagliflozin / Empagliflozin (SGLT2 inhibitors) – Dose: dapagliflozin 10 mg daily; empagliflozin 10 mg daily (eGFR limits apply). Purpose: slow CKD progression and lower albuminuria; strongest evidence in diabetic CKD; emerging in non-diabetic CKD. Mechanism: tubuloglomerular feedback lowers intraglomerular pressure. Side effects: genital mycotic infection, volume depletion; hold during acute illness. KDIGO+2Kidney International+2
Finerenone (non-steroidal MRA) – Dose: 10–20 mg daily (for diabetic CKD with albuminuria). Purpose: further reduces kidney/cardiac risk. Side effects: ↑potassium; monitor closely. PubMed
Spironolactone/Eplerenone (steroidal MRA; off-label adjunct) – Low-dose add-on for resistant proteinuria (specialist use). Side effects: ↑potassium; gynecomastia with spironolactone. PMC
CKD metabolic care
Sodium bicarbonate – 650 mg tablets 1–3×/day as guided. Purpose: treat metabolic acidosis in CKD. Mechanism: buffers acid. Side effects: bloating, sodium load (watch BP). KDIGO
Sevelamer carbonate – 800–1600 mg with meals. Purpose: lower high phosphorus in advanced CKD. Mechanism: binds phosphate in gut. Side effects: GI upset, constipation. KDIGO
Calcitriol or active vitamin D analogs – tiny doses as guided. Purpose: CKD-MBD management when PTH high. Side effects: high calcium/phosphate. KDIGO
Cholecalciferol (vitamin D3) – repletion/maintenance per level. Purpose: correct deficiency common in CKD. Side effects: hypercalcemia if excessive. KDIGO
Atorvastatin – 10–40 mg/day adults. Purpose: atherosclerotic risk reduction in CKD. Side effects: myalgia, rare liver enzyme rise. KDIGO
Anemia and elliptocytosis care (as needed)
Oral iron (e.g., ferrous sulfate) – 65 mg elemental iron 1–3×/day if deficient. Purpose: treat iron-deficiency anemia. Mechanism: builds hemoglobin. Side effects: nausea, constipation. (Use IV iron if oral not tolerated.) KDIGO
Erythropoiesis-stimulating agents (epoetin alfa/darbepoetin) – dosing individualized. Purpose: treat CKD anemia when iron replete. Side effects: ↑BP, thrombosis risk when over-corrected. KDIGO
Folic acid – 1 mg/day commonly used in chronic hemolysis to support RBC production (dose varies by age). Side effects: very well tolerated. Medscape+1
Ursodeoxycholic acid – dose per weight if cholestasis/gallstones symptoms present; sometimes used around gallstone disease in hemolysis (specialist guided). Revista Nefrología
Short-course antibiotics – for post-splenectomy fever or proven infections, per local guidelines; lifesaving in asplenia. Side effects: drug-specific. UpToDate
Vaccines (medications given to prevent infections) – pneumococcal, Hib, meningococcal, influenza, others per schedule; especially crucial if splenectomized. Side effects: transient soreness/fever. UpToDate
Dietary molecular supplements
Folic acid – 1 mg/day in significant hemolysis (or per age-specific dosing). Function: supports DNA synthesis for red cells. Mechanism: folate pathway. Medscape
Iron – dose based on ferritin/TSAT. Function: rebuilds hemoglobin if iron-deficient. Mechanism: heme synthesis. KDIGO
Vitamin B12 – dose guided by level. Function: supports RBC maturation; low B12 worsens anemia. Mechanism: DNA synthesis. Frontiers
Vitamin D3 (cholecalciferol) – repletion if low. Function: bone health in CKD. Mechanism: improves calcium-phosphate balance. KDIGO
Active vitamin D (calcitriol) – only if prescribed for CKD-MBD. Function: suppresses high PTH. Mechanism: active hormone form. KDIGO
Omega-3 fatty acids – typical 1–2 g/day EPA/DHA; limited evidence for proteinuria reduction; may aid CV health. Mechanism: anti-inflammatory. (Discuss with nephrologist.) KDIGO
Bicarbonate (oral) – as tablets/powder if acidotic (dose per labs). Function: corrects CKD acidosis. Mechanism: buffer. KDIGO
Calcium carbonate (as binder) – with meals if phosphorus high (only under guidance to avoid high calcium). Function: binds dietary phosphate. KDIGO
Zinc (if low) – replaces deficiency; may support taste/appetite in CKD. Mechanism: cofactor for enzymes. (Check level first.) KDIGO
Thiamine (if low) – CKD and poor intake can reduce levels; replacement improves energy metabolism. Mechanism: carbohydrate metabolism. KDIGO
Immunity booster / regenerative / stem-cell” drugs
There are no approved stem-cell or gene-editing drugs for this syndrome today. Research is active in Alport syndrome (AAV gene therapy, exon-skipping, and mesenchymal stem cells) but is preclinical or early-phase and not standard care. If you are interested, speak with your nephrologist about clinical trials. Safe “immune boosters” as drugs do not exist for this condition; instead, proven prevention is routine vaccination, nutrition, and prompt treatment of infections. ClinicalTrials.gov+6PMC+6Nature+6
What researchers are testing (informational, not prescriptions):
AAV9 gene therapy targeting COL4A5/COL4A3 in animal models. Lippincott Journals+1
Antisense exon-skipping to bypass specific COL4A5 mutations (preclinical). Nature
Mesenchymal stem cells in early human trials for Alport (safety/efficacy under study). CenterWatch+1
Surgeries and procedures
Kidney transplantation – for end-stage kidney disease. Purpose: restore kidney function and quality of life. (Alport does not recur in the graft, though anti-GBM disease is a rare complication.) PMC
Dialysis access creation – AV fistula for hemodialysis or peritoneal dialysis catheter if dialysis becomes necessary. Purpose: life-sustaining therapy while awaiting transplant. PMC
Cochlear implantation – for severe sensorineural hearing loss when hearing aids are not enough. Purpose: improve speech perception and communication. PMC
Splenectomy – for severe elliptocytosis with significant hemolysis and transfusion needs. Purpose: reduce RBC destruction and improve anemia; often paired with strict vaccination plan; sometimes cholecystectomy is done if gallstones are problematic. Medscape+2NCBI+2
Cholecystectomy – if symptomatic gallstones from chronic hemolysis. Purpose: relieve pain, prevent biliary complications. Revista Nefrología
Prevention strategies
Keep blood pressure controlled (home logs + clinic follow-up).
Start and optimize ACEi/ARB early when advised to reduce proteinuria. Kidney International
Avoid kidney-toxic drugs (NSAIDs, aminoglycosides when avoidable). PMC
Low-salt eating most days of the week. KDIGO
Treat infections promptly; fever after splenectomy is an emergency. UpToDate
Up-to-date vaccines, especially if asplenic. UpToDate
Regular audiology and vision checks to catch changes early. PMC
Folate support if ongoing hemolysis (diet/supplement). Medscape
Genetic counseling for family planning and cascade testing. Frontiers
Plan ahead for kidney replacement therapy if function declines. PMC
When to see doctors urgently
New or worsening swelling, breathlessness, very high blood pressure, or a big drop in urine amount.
Brown or red urine, especially with pain or fever.
Rapid hearing changes or sudden vision symptoms.
Signs of anemia or hemolysis: extreme tiredness, pale skin, yellow eyes/skin, dark urine, or abdominal pain from gallstones.
Fever after splenectomy (seek immediate care). PMC+1
What to eat and what to avoid
Eat: mostly unprocessed foods with low salt (fresh vegetables, fruits suited to your potassium plan, whole grains in moderation).
Choose lean proteins in amounts your nephrologist/dietitian recommends; avoid very high-protein fad diets.
Prefer plant oils, nuts (portion-controlled), and fish for heart health.
If hemolysis is present, include folate-rich foods (leafy greens, beans, fortified grains). Medscape
If iron-deficient, add iron-rich foods (lean red meat, pulses) plus vitamin C sources to aid absorption (if allowed for CKD).
Limit high-phosphate processed foods and colas; use phosphate binders only if prescribed. KDIGO
Limit added sugars and refined carbs for weight/BP control.
Avoid high-salt snacks and instant foods; read labels.
Avoid herbal or “detox” products with kidney-toxic ingredients (e.g., aristolochic acid).
Avoid star fruit and other known neurotoxic fruits in advanced CKD; follow your care team’s potassium/fluid limits. KDIGO
Frequently asked questions
Is this the same as classic Alport syndrome?
Not exactly. It includes Alport syndrome but also adds intellectual disability, midface hypoplasia, and elliptocytosis because nearby genes beyond COL4A5 are deleted together. FrontiersHow is it inherited?
Usually X-linked. People with one X (typically males) are usually more affected; those with two X’s may be carriers with mild or no symptoms. Orpha.netWhich genes are involved?
At minimum COL4A5; often AMMECR1 and ACSL4 (FACL4) and sometimes other neighbors in Xq22.3. PMC+1What are the first signs?
Microscopic hematuria/proteinuria, gradual hearing loss, midface features, and sometimes anemia from elliptocytosis. FrontiersIs there a cure?
No cure yet. We slow kidney damage with ACEi/ARB and careful CKD care. Transplant treats kidney failure. Research on gene and stem-cell therapies is ongoing. PMC+1Do all patients get anemia?
No. Many have elliptocytosis without anemia. When hemolysis is significant, folate and sometimes splenectomy are considered. MedscapeWill hearing always get worse?
Hearing loss tends to progress in Alport syndrome; early audiology, hearing aids, and cochlear implant evaluation help function. PMCWhat about the eyes?
Some get characteristic eye findings (e.g., anterior lenticonus); regular eye checks are important. PMCCan women be affected?
Yes. Carriers can have hematuria, proteinuria, and even kidney decline or hearing loss; monitoring is important. PMCAre SGLT2 inhibitors for everyone?
Best evidence is in diabetic CKD; some nephrologists use them in non-diabetic proteinuric CKD, but decisions are individualized. Kidney International+1Are there medicines to avoid?
Avoid NSAIDs when possible, aminoglycosides unless essential, and be careful with IV contrast; always tell providers you have kidney disease risk. PMCDoes Alport come back in a kidney transplant?
The genetic defect does not recur in the new kidney, but a rare anti-GBM reaction can occur; transplant teams monitor for this. PMCCan children live a normal life?
With early care, school supports, and kidney/hearing management, many children do very well. Lifelong follow-up is needed. PMCShould family members be tested?
Yes—cascade genetic testing helps identify relatives who need monitoring or prenatal options. FrontiersWhere can I learn about trials?
Check ClinicalTrials.gov and the Alport Syndrome Foundation for current studies and eligibility. ClinicalTrials.gov+1
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 14, 2025.
Alport Deafness-Nephropathy
